Roivant Sciences
ROIV

Roivant Sciences (ROIV) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Wolfe ResearchDowngradedOutperform → Peer Perform—Oct 12, 2026
StifelInitiated CoverageBuy$51.00Sep 17, 2026
GuggenheimMaintainedBuy$46.00 from $42.00Sep 9, 2026
TD CowenMaintainedBuy$55.00 from $50.00Sep 9, 2026
JefferiesMaintainedBuy$52.00 from $42.00Sep 8, 2026
HC Wainwright & Co.MaintainedBuy$47.00 from $41.00Sep 8, 2026
HC Wainwright & Co.MaintainedBuy$41.00Aug 28, 2026
CitigroupMaintainedBuy$46.00 from $42.00Aug 10, 2026
HC Wainwright & Co.MaintainedBuy$41.00 from $34.00Aug 7, 2026
GuggenheimMaintainedBuy$42.00 from $36.00Aug 7, 2026
GuggenheimMaintainedBuy$36.00 from $30.00May 26, 2026
HC Wainwright & Co.MaintainedBuy$34.00May 21, 2026
CitigroupMaintainedBuy$42.00 from $35.00May 21, 2026
TD CowenMaintainedBuy$41.00 from $38.00May 21, 2026
Piper SandlerMaintainedOverweight$40.00 from $22.00Apr 16, 2026
HC Wainwright & Co.MaintainedBuy$34.00 from $33.00Mar 4, 2026
HC Wainwright & Co.MaintainedBuy$33.00 from $26.00Feb 10, 2026
CitigroupMaintainedBuy$35.00 from $26.00Feb 10, 2026
GuggenheimMaintainedBuy$30.00 from $28.00Feb 9, 2026
Goldman SachsMaintainedBuy$33.00 from $24.00Dec 15, 2025

Frequently asked questions

  • What is the latest analyst rating on ROIV?

    On Oct 12, 2026, Wolfe Research downgraded Roivant Sciences to Peer Perform.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.